Axsome Therapeutics

Company snapshot

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives o

• 2 approved product(s) across US/EU regulatory metadata.
• 28 active pipeline program(s) linked via ClinicalTrials.gov.
• 162 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Axsome Therapeutics. Not investment advice.

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for Axsome Therapeutics.

1. Jun 8, 2026 Clinical update

   SOL-BED-303 — Phase 3

2. Jun 8, 2026 Clinical update

   Solriamfetol Oral Tablet — Approved

3. Jun 8, 2026 Clinical update

   Solriamfetol 150 mg Oral Tablet — Phase 1

4. Jun 8, 2026 Clinical update

   AXS-07 (MoSEIC meloxicam and rizatriptan) — Phase 3

5. Jun 8, 2026 Clinical update

   AXS-07 (meloxicam-rizatriptan) — Phase 3

View all clinical trial activity →

• What is Axsome Therapeutics?

  Axsome Therapeutics is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker AXSM. Primary therapeutic focus areas include Major Depressive Disorder, Migraine, Agitation in Patients With Dementia of the Alzheimer's Type, Narcolepsy, Binge-Eating Dis

• Is Axsome Therapeutics publicly traded?

  Yes. Axsome Therapeutics is listed with ticker AXSM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Axsome Therapeutics develop or market?

  We link 12 drug profile(s) where Axsome Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/axsome-therapeutics#company-drugs.

• What are the latest developments for Axsome Therapeutics?

  In the last 12 months our linked public records show 28 trial program update(s) and 6 US patent grant(s) tied to this profile.

• What therapeutic areas does Axsome Therapeutics focus on?

  Axsome Therapeutics focuses on Major Depressive Disorder, Migraine, Agitation in Patients With Dementia of the Alzheimer's Type based on our analysis of their pipeline programs and drug development activities.